Phase 3 data and practical implications for your protocol Phase 3 data extended the timeline to 68 weeks and pushed peak weight loss to 28.7 percent, equivalent to 71.2 pounds or 32.3 kilograms in the highest-performing participants
The SELECT trial, as noted earlier, went a step further it tested Wegovy in overweight/obese individuals with cardiovascular disease (but without diabetes) and found a 20% reduction in heart attacks, stroke, or CV death ( [67] )
Goldman Sachs recently trimmed its forecast for the anti-obesity drug market
Some studies suggest omega-3 supplementation may modestly affect GLP-1 levels, though results are mixed and clinical significance uncertain
It does not impact muscle tissue
Unlike traditional medications, peptides mimic the bodys natural signaling molecules, leading to fewer side effects and more targeted results